Your browser doesn't support javascript.
Prevalence, risk factors, treatment and outcome of multidrug resistance Candida auris infections in Coronavirus disease (COVID-19) patients: A systematic review.
Vinayagamoorthy, Kalaiselvi; Pentapati, Kalyana Chakravarthy; Prakash, Hariprasath.
  • Vinayagamoorthy K; Centre for Public Health (U.I.E.A.S.T), Panjab University, Chandigarh, India.
  • Pentapati KC; Department of Public Health Dentistry, Manipal College of Dental Sciences, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.
  • Prakash H; Medical Microbiology, Department of Public Health, International Higher School of Medicine, Cholpon-Ata, Kyrgyzstan.
Mycoses ; 65(6): 613-624, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1794602
ABSTRACT

BACKGROUND:

Candida auris is an emerging multidrug-resistant pathogen in intensive care settings (ICU). During the coronavirus disease 19 (COVID-19) pandemic, ICU admissions were overwhelmed, possibly contributing to the C. auris outbreak in COVID-19 patients.

OBJECTIVES:

The present systematic review addresses the prevalence, underlying diseases, iatrogenic risk factors, treatment and outcome of C. auris infections in COVID-19 patients.

METHODS:

MEDLINE, Scopus, Embase, Web of Science and LitCovid databases were systematically searched with appropriate keywords from 1 January 2020 to 31 December 2021.

RESULTS:

A total of 97 cases of C. auris were identified in COVID-19 patients. The pooled prevalence of C. auris infections (encompassing candidemia and non-candidemia cases) in COVID-19 patients was 14%. The major underlying diseases were diabetes mellitus (42.7%), hypertension (32.9%) and obesity (14.6%), followed by the iatrogenic risk factors such as a central venous catheter (76.8%%), intensive care unit (ICU) stay (75.6%) and broad-spectrum antibiotic usage (74.3%). There were no significant differences in underlying disease and iatrogenic risk factors among C. auris non-candidemia/colonisation and C. auris candidemia cases. The mortality rate of the total cohort is 44.4%, whereas, in C. auris candidemia patients, the mortality was 64.7%.

CONCLUSION:

This study shows that the prevalence of C. auris infections remains unchanged in the COVID-19 pandemic. Hospital-acquired risk factors may contribute to the clinical illness. Proper infection control practices and hospital surveillance may stop future hospital outbreaks during the pandemic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Candidemia / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: Mycoses Journal subject: Microbiology Year: 2022 Document Type: Article Affiliation country: Myc.13447

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Candidemia / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: Mycoses Journal subject: Microbiology Year: 2022 Document Type: Article Affiliation country: Myc.13447